Startup profile for Wilco (healthcare patient follow-up): latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Wilco (healthcare patient follow-up) funding, valuation and investors

AI voice and WhatsApp agents for clinic groups, tracking patients from first inquiry to an attended visit, accepted treatment plan and return appointment.

Verified company research · funding, investors and latest developments

Keep track of Wilco (healthcare patient follow-up)

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Funding round (stage undisclosed)

€2.5M · November 19, 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

Stage not recorded · Madrid, Spain

Investors in latest funding

Lead: Samaipata

Other: ABAC Nest Ventures , Unnamed technology and healthcare executives

Sources: latest funding · europapress.es Last verified: 2026-11-21

Overview

Founded by Francisco Hernández Parga, Wilco sells AI-assisted follow-up workflows to healthcare clinic groups, including dental, ophthalmology, aesthetics and veterinary networks. Its system is not primarily a diagnostic agent: it handles missed calls and web enquiries, offers callbacks, coordinates appointments, helps patients navigate decisions on offered treatment plans and follows up on overdue care.

Clinicians remain responsible for clinical advice; human support and escalation are part of the product.

In a company-disclosed financing announced November 19, 2026, Wilco raised €2.5M led by Samaipata. ABAC Nest Ventures and unnamed technology and healthcare executives also participated. Neither a formal Seed/Series A classification, valuation, each investor's contribution nor the legal closing date was specified in the original disclosure.

Proceeds are intended for engineering, implementation, sales and planned growth into Europe, the US and Latin America.

An illustrative buyer workflow based on Wilco's own demonstration begins with a missed clinic enquiry; the software triggers a callback, asks when the patient can speak, follows up through WhatsApp, offers a real available clinic slot, records the booking in clinic systems, and sends attendance reminders. After a visit it can follow up on pending treatment plans or recalls, escalating clinical questions to licensed staff.

Forward-deployed engineers set up each deployment with local systems and agree metrics. The vendor advertises three to eight weeks to go live depending on integration requirements. There is no verified public subscription price or full integration catalog.

The website says it has handled over 1.5M patient calls and messages and uses selected client logos including Clínica Baviera and WM Clinics. It claims a dental group with 80-plus clinics raised lead-to-attendance conversion from 20% to 25%; that is a five-percentage-point and 25% relative gain, not 25 percentage points. Another selected aesthetics example claims +15% lead-to-booking.

These are vendor-reported selected results, not independent experiments. A much larger possible economic impact from dormant-patient reactivation mentioned in Spanish media is a forecast, NOT recognized Wilco revenue or audited benefit.

Alternatives include staffed clinic call centres, appointment reminder systems, healthcare CRM automation and receptionist-only AI platforms. Buyers should compare attended-visit lift, opt-out enforcement, consent for voice/WhatsApp contact, treatment-plan accuracy, escalation and audit logs, integration with practice-management records and real cost per attended visit.

No audited ARR, gross margin, external clinical efficacy study or independent ROI dataset was found.

Why Wilco (healthcare patient follow-up) is interesting

The €2.5M round led by Samaipata on November 19, 2026 targets a measurable workflow—turning expensive patient leads into actual attended consultations. The formal round stage and valuation remain undisclosed.

Product & use cases

Illustrative first-visit journey, not a VCT hands-on test: 1) a patient submits a web enquiry; 2) Wilco calls or messages back; 3) the patient asks for a later time; 4) an agent checks real calendar availability and books a clinic visit; 5) a reminder or reschedule is saved to the clinic system; 6) unresolved clinical questions are handed to staff and a permitted return-visit workflow follows.

  • Dental network: recover abandoned enquiries and no-show appointments
  • Ophthalmology/aesthetic clinics: follow up on pending treatment plans without giving clinical advice
  • Veterinary practices: arrange opt-in recalls and preventative visits

Funding history (newest first)

Funding round (stage undisclosed)

2026-11-19 €2.5M

Source: Read source · europapress.es

Investors in our directory

Funds linked from Wilco (healthcare patient follow-up)'s profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Vendor-positioned differentiator is follow-up from inquiry through actual attendance and treatment acceptance, rather than calls answered; deployments are configured with clinic IT teams. Independent comparative efficacy and fees undisclosed.

Wilco competes for operational budgets previously spent on reception, call centres, CRM follow-up and patient acquisition waste. Compare per attended visit and signed care plan, not per call answered; validate patient consent and clinical-safety limitations.

  • Clinic call centres incumbent

    Human service alternative with variable staffing costs and continuity.

  • Weave adjacent

    Patient communication suite; compare live system integrations and automated care follow-up.

  • Hello Patient adjacent

    AI receptionist and booking; assess scope beyond first appointment.

  • Tucuvi adjacent

    Healthcare voice automation emphasizing other care-management workflows.

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Wilco (healthcare patient follow-up)

Practical answers founders, operators, and investors typically search for.

No official stage was disclosed in the November 19, 2026 announcement; it should be described as a funding round, not asserted to be Series A or Seed.
The company requires a buyer consultation and has not verified a public standardized fee schedule.
No independent controlled assessment was found; the figures are selected company-published examples.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.